Arbutus Biopharma Corp (ABUS NASDAQ) stock market data APIs
$4.4217
-0.03(-0.7%)
as of September 17, 2025
Try our APIs with
free plan!
Arbutus Biopharma Corp Financial Data Overview
Price chart is built with
Anychart
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Prev. Close
4.4217
Open
4.3951
High
4.5103
Low
4.3957
52 wk Range
2.705-5.1
Market Cap
843 M
Shares Outstanding
192 M
Revenue
15 416 K
EPS
0.01
Beta
1.006
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Arbutus Biopharma Corp (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Arbutus Biopharma Corp data using free add-ons & libraries
Get Arbutus Biopharma Corp Fundamental Data
Arbutus Biopharma Corp Fundamental data includes:
- Net Revenue: 15 416 K
- EBITDA: -43 243 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: -0.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Arbutus Biopharma Corp News
New
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Novartis (NVS) been one of those stocks this year? A quick gl...
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
Arbutus Biopharma (ABUS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.11 per share a year ago. ...
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignati...
Arbutus Biopharma Reacquires China Rights To Imdusiran
(RTTNews) - Arbutus Biopharma (ABUS) has reacquired China rights to its lead compound, imdusiran, from Qilu Pharmaceutical, a pharmaceutical company in China. The companies have mutually agreed to con...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
